Skip to main content
Premium Trial:

Request an Annual Quote

Marc Hodosh, Andrew Wooten, Nava Whiteford

Marc Hodosh has stepped down as senior director of the X Prize Foundation and leader of the Archon X Prize for Genomics, In Sequence has learned.
He was replaced by Andrew Wooten last month, who joined the X Prize Foundation from Arizona Technology Enterprises, the technology commercialization company for Arizona State University, where he was vice president of health science ventures. Previously, Wooten held business development positions at Applied Biosystems and Thermo Fisher Scientific.
Hodosh, who joined the X Prize Foundation last year, has become president of TED MED, a conference he plans to re-launch next year. He remains a senior advisor to the X-Prize Foundation, according to its website.

Nava Whiteford has joined Oxford Nanopore Technologies as a senior computational scientist. He comes to the nanopore sequencing company from the Wellcome Trust Sanger Institute, where he was a bioinformatician.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.